Evaluation of SpeeDx PlexPrime® and PlexZyme® technology published in PLOS One
SpeeDx Pty. Ltd. announced the publication of a novel technology, ‘Superior Multiplexing Capacity of PlexPrimers Enables Sensitive and Specific Detection of SNPs and Clustered Mutations in qPCR’ in PLOS One this week. The authors concluded that, unlike previously used qPCR techniques, SpeeDx’s unique qPCR technology, using PlexPrimers® with PlexZymes® enables both allele-specific detection and amplification in qPCR. The study demonstrated highly sensitive and specific detection of mutations, deletions and SNPs, and superior multiplexing capacity. The ability to multiplex clustered genetic variants reduces the time to result providing more actionable information.
“Our proprietary rapid qPCR technology demonstrates distinct advantages in test specificity and sensitivity (accuracy) compared to other multiplex qPCR technologies. We have advanced the detection of genetic mutations and viral and bacterial diseases in a single reaction well, resulting in more actionable information for labs and doctors, higher throughput and better patient care,” said Colin Denver, CEO of SpeeDx.
2017 has been very promising for SpeeDx so far, and this publication is just another part of what has been a great start to the year.
For the full publication click here.